Compare NetApp Inc. (NTAP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Summit Therapeutics Inc — how do they compare? NetApp Inc. trades at $184 (market cap $36.29B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.98B). The key difference: NetApp Inc. is far larger — about 2.6× Summit Therapeutics Inc's market cap, and NetApp Inc. pays a 1.13% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NTAP | SMMT | |
|---|---|---|
Market Cap | $36.29B | $13.98B |
Sector | Technology | Health |
52-Week High | $207.08 | $26.38 |
52-Week Low | $94.11 | $12.43 |
Enterprise Value | $35.24B | $13.31B |
Dividend Yield | 1.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $189.13, up 1.91% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows robust fundamentals, including a 70.63% gross margin and 19.19% net income margin, supported by record quarterly results and raised fiscal 2027 guidance. Analyst consensus is a buy with a $193.55 price target, though valuation metrics like a P/E of 26.71 indicate a premium. Recent news highlights AI-driven demand and cloud growth as key catalysts.
Outlook remains positive due to AI storage momentum and operational strength, but risks include premium valuation pressure and margin challenges. The stock offers growth potential from hybrid cloud expansion, yet investors should monitor execution against high expectations and competitive dynamics in the data infrastructure sector.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, while P/B stands at 22.19. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancer, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.18 suggesting 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish with 61% buy ratings, but the stock remains speculative due to its pre-revenue status and dependence on a single drug candidate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
